• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Let's review the charts and indicators.
By BRUCE KAMICH
Feb 23, 2021 | 07:43 AM EST
Stocks quotes in this article: LLY

For his second "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with David Ricks, chairman and CEO of Eli Lilly (LLY) , the pharmaceutical giant.

Ricks first spoke of Lilly's progress with Donanemab, a treatment for Alzheimer's disease. He said Donanemab could be a game changer. In Phase 2 trials, it has proven to quickly eliminate plaque in the brain that triggers the disease. The one-time treatment can remove plaque that builds up over 20 years and is effective in helping early-stage Alzheimer's patients achieve better outcomes.

In addition to Phase 3 testing, Lilly is also studying whether Donanemab could also be used as a one-time preventative measure for everyone, even before symptoms start.

Ricks was also upbeat on the outlook for Covid-19. He said Lilly's Covid therapies are working against most variants of the disease and overall, vaccines are winning the war. He predicted that by April, the U.S. will have more doses of vaccines than demand.

Let's check out the charts and indicators to round out the analysis.

In this daily bar chart of LLY, below, we can see that prices have sprinted higher from early November. LLY has been correcting sideways to lower since late January. Prices are still above the rising 50-day and the rising 200-day moving average lines. The trading volume was heavy in January and has diminished so far this month. This suggests there may be a fair amount of new longs at a high price.

The On-Balance-Volume (OBV) line has weakened since late January telling us that sellers of LLY have been more aggressive.

The Moving Average Convergence Divergence (MACD) oscillator crossed to the downside in late January for a take profit sell signal. The indicator is pointed down but still above the zero line.

In this weekly Japanese candlestick chart of LLY, below, we can see in late January a weekly long-legged doji pattern (top reversal) followed by confirmation (a red real body) the following week.

The 40-week moving average line is still positive but the OBV line has begun to weaken and the MACD oscillator has been narrowing.

In this daily Point and Figure chart of LLY, below, we can see a potential downside price target in the $174 area. This is a partial filling of the price gap on the daily bar chart. The entire gap could get filled.

In this second Point and Figure chart of LLY, below, we used weekly close only price data. Here the software shows the $357 area as a potential longer-term price target.

Bottom line strategy: If you have no patience to sit through a correction of a really unknown proportion and timing I would take your profits and sit this out for several weeks. Longer-term, LLY's new drug could be a huge blockbuster. We'll see.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals | Mad Money | Executive Interview

More from Investing

Corrective Action Produces Fading Confidence and Technical Damage

James "Rev Shark" DePorre
Feb 26, 2021 5:08 PM EST

It's dangerous to have too much exposure now, but the potential for a good recovery is there once interest rate issues are digested.

I'm Intrigued by the Recent Pullback in Aurora Mobile

Timothy Collins
Feb 26, 2021 3:30 PM EST

While the Chinese company is still not profitable, it is cash flow positive.

Salesforce Gets a Quant Downgrade on Top of Weakening Charts

Bruce Kamich
Feb 26, 2021 12:50 PM EST

Here's what investors and traders need to think about.

My Preference Right Now Is to Buy Pre-Deals

Timothy Collins
Feb 26, 2021 12:36 PM EST

I've added a few names that I see as a great risk-reward because of the limited downside.

I've Been a Buyer Friday, Making Partial Buys Like I Always Do

James "Rev Shark" DePorre
Feb 26, 2021 12:07 PM EST

It's premature to predict that a low has been made, but plenty of stocks are quite washed-out already and are starting to find support.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login